High-Risk Heart Patients Get a Second Chance at Dallas Valve Institute
The Dallas Valve Institute at Medical City (DVI) is a leading-edge medical facility dedicated to developing advanced cardiovascular treatments that save lives and restore hope in patients. When patients are turned down for complex heart surgeries at other hospitals, DVI acts as their one stop for treatment.
Each year, more than 200,000 Americans suffer from severe aortic stenosis.
The team at Dallas Valve Institute is here to help. We are proud to be a part of HCA Healthcare, which performs three times more transcatheter aortic valve replacement (TAVR) procedures than any other health system.
Pioneers in Beating Heart Surgeries
At the forefront of cardiovascular technology are Dr. Bruce Bowers, Medical Director of Invasive and Noninvasive Cardiology for Medical City Dallas and HCA National Medical Director for Interventional Cardiology, and Dr. Todd Dewey, Medical Director of Structural Heart, Heart Transplant and Medical Assist Device for Medical City Dallas and HCA National Medical Director of Cardiovascular Surgery. Together they lead medical breakthroughs through research and innovations in beating-heart aortic valve replacement surgery, world-class heart transplant program and a state-of-the-art vascular lab.
What is Aortic Stenosis?
When blood leaves a healthy heart, it flows through the aortic valve and into the aorta, the body's main artery. But in patients with aortic stenosis, the aortic valve doesn't fully open. Instead, it narrows, and the blood flow from the heart decreases. This narrowing increases the pressure inside the heart, which can lead to pain and even death.
What are the Treatment Options?
Open-heart surgery is commonly required to repair or replace their narrowed valves. Many older patients, however, are diagnosed as too weak to survive open-heart surgery. In the past, there was little physicians could do. Today, however, a new treatment is giving those patients a second chance at life.
Dallas Valve Institute was one of the first facilities in the country to perform the transcatheter aortic valve replacement (TAVR) procedure — a new minimally invasive treatment for severe aortic stenosis.
Minimally Invasive Mitral Valve Repair
In August 2015, Dr. Bowers and Dr. Dewey implanted the first MitraClip with great success.
MitraClip is the only FDA-approved percutaneous therapy for degenerative mitral disease, and this technology is used for those patients with prohibitive risk for open heart procedures.
They performed the MitraClip on a 72-year-old patient, and we were able to capture her on video the day after her procedure. The outcome was great for her. She could not have undergone another cardiac procedure, and the MitraClip was the only option for her. We will be screening patients for this therapy in the Dallas Valve Institute.
Effectiveness of MitraClip® therapy for severe degenerative mitral regurgitation (DMR)
Certain high-surgical-risk patients with severe degenerative mitral regurgitation (DMR) now have a minimally invasive treatment option. MitraClip® therapy is a minimally-invasive transcatheter mitral valve repair (TMVr) procedure that has been established as a proven option with demonstrated safety and clinically important improvements.
Used in more than 25,000 patients worldwide, MitraClip® is a well-established therapy. The MitraClip® device received CE Mark approval in Europe in 2008 and U.S. FDA approval in 2013, and has been approved for commercial use in 50 countries throughout the world.
PARTNER III Clinical Trial for Aortic Stenosis Patients with Low Surgical Mortality Risk
Medical City Heart and Vascular and Dallas Valve Institute (DVI) are participants of the Edwards PARTNER III TAVR clinical trial for structural heart treatment.
Low- and normal-risk heart patients may now be candidates for transcatheter aortic valve replacement (TAVR) as part of the PARTNER 3 clinical trial. Elderly patients with symptomatic, severe aortic stenosis requiring aortic valve replacement and who meet other criteria may be eligible for this trial.
Approved by the U.S. Food and Drug Administration in 2016, the PARTNER III clinical trial studies the safety and outcomes for the Edwards Sapien 3 valve in patients with low risk for mortality in surgery. Sapien 3 is an innovative transcatheter heart valve (THV) device that facilitates minimum paravalvular leakage (PVL) during deployment in aortic stenosis (AS) patients.
Please feel free to reach out to the Dallas Valve Institute team at (972) 566-5050 if you have specific questions regarding the PARTNER III clinical trial, patient qualification, other offered procedures or general questions.
The Dallas Valve Institute Clinical Team
Lisa Johnson is an Acute Care Nurse Practitioner at Medical City Dallas. She obtained her master’s in nursing from the University of Texas Arlington in 2000 and began her nursing career in the trauma ICU. She has worked at Medical City Dallas working in cardiothoracic surgery and cardiology for 17 years. Lisa is passionate about extending and improving each patient’s quality of life. In her role, she focuses on educating patients so they are able to make informed decisions and become active participants of their care.